Browse Studies — Arctuva

Phase 3

A Phase 3a, Observer-blind, Randomized, Controlled Study to Demonstrate Lot-to-lot Consistency and Evaluate the Immunogenicity and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine Compared With ProQuad, Administered as a Second Dose in Healthy Children 4-6 Years of Age

The purpose of this study is to evaluate how consistently 3 different manufacturing lots of the GSK's investigational measles, mumps, rubella, and varicella (M…

MeaslesMumpsRubella+2 more

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT07742644

Phase 3

A Phase 3a, Observer Blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Combined Measles, Mumps, Rubella, and Varicella Vaccine Compared With Intramuscular Administration of ProQuad When Administered as a Second Dose to Healthy Children Aged 15 Months to 6 Years of Age

This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administ…

MeaslesMeasles-Mumps-Rubella+Chickenpox Vaccine

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT07406360

Verifying Antibodies After Live Immunization Delivery (VALID): a Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease

The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged …

Sickle Cell DiseaseMeasles VaccinationSickle Cell Anemia

Estimated

~$10 – $675

Children's Hospital Medical Center, CincinnatiNCT07356050